To our knowledge, this is the first study to report on PCSM rates in response to the USPSTF Grade D recommendation against PSA screening for all men using comprehensive, contemporary population-based data over 20 years (1999-2019), along with comparison with rates of localized and metastatic prostate cancer diagnoses. Here, KLK3 is linked to metastatic prostate carcinoma.